beta
IA Trial Radar
O estudo clínico NCT07497386 para Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer está ainda não recrutando. Consulte a visualização em cartões do Radar de Estudos Clínicos e as ferramentas de descoberta de IA para ver todos os detalhes. Ou pergunte qualquer coisa aqui.
Um estudo corresponde aos critérios do filtro
Visualização em cartões
Voltar à pesquisa

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer Fase II 150

Ainda não recrutando
Os detalhes do estudo clínico estão disponíveis principalmente em inglês. No entanto, a IA Trial Radar pode ajudar! Basta clicar em 'Explicar o estudo' para visualizar e discutir as informações do estudo no idioma selecionado.
O estudo clínico NCT07497386 vai avaliar tratamento para Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer. Este é um estudo intervencionista de Fase II. Seu status atual é: ainda não recrutando. O recrutamento está programado para iniciar em 1 de abril de 2026, com o objetivo de incluir 150 participantes. Coordenado por HENGRUI PHARMA e deve ser concluído em 1 de dezembro de 2028. Essas informações foram atualizadas no ClinicalTrials.gov em 27 de março de 2026.
Resumo
The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
Título oficial

A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression

Condições médicas
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast Cancer
Outros IDs do estudo
  • SHR-A1811-217
Número NCT
NCT07497386
Data de início (real)
2026-04
Última atualização postada
2026-03-27
Data de conclusão (estimada)
2028-12
Inscrição (estimada)
150
Tipo de estudo
Intervencionista
FASE
Fase II
Status
Ainda não recrutando
Propósito principal
Tratamento
Alocação do design
Randomizado
Modelo de intervenção
Paralelo
Cegamento (Mascaramento)
Nenhum (Aberto)
Braços / Intervenções
Grupo de participantes/BraçoIntervenção/Tratamento
ExperimentalTrastuzumab Rezetecan for Injection
Trastuzumab Rezetecan for Injection, different doses.
Trastuzumab Rezetecan for Injection
Trastuzumab Rezetecan for injection.
ExperimentalTrastuzumab Deruxtecan for Injection
Trastuzumab Deruxtecan for Injection
Trastuzumab Deruxtecan for injection.
Desfecho primário
Medida de desfechoDescrição da medidaPrazo
Progression-free survival (PFS).
Every 6 weeks after administration, approximately 14 months.
Desfecho secundário
Medida de desfechoDescrição da medidaPrazo
Objective response rate (ORR).
Every 6 weeks after administration, approximately 14 months.
Duration of response (DoR).
Every 6 weeks after administration, approximately 14 months.
Clinical benefit rate (CBR).
Every 6 weeks after administration, approximately 14 months.
Adverse events (AEs).
Graded according to NCI-CTCAE version 5.0.
From the first dose administration until 40 days after the last dose administration.
Laboratory test indicators, including complete blood count.
From the first dose administration until 40 days after the last dose administration.
Laboratory test indicators, including urinalysis.
From the first dose administration until 40 days after the last dose administration.
Laboratory test indicators, including virology screening.
From the first dose administration until 40 days after the last dose administration.
Serum concentrations of Trastuzumab Rezetecan.
Until the end of treatment, approximately 14 months.
Assistente de participação
Critérios de elegibilidade

Idades elegíveis
Adulto, Idoso
Idade mínima
18 Years
Sexos elegíveis
Feminino
  1. Female aged 18 to 75 years (inclusive).
  2. Unresectable locally recurrent or metastatic breast cancer.
  3. Prior therapy must meet the following: No prior chemotherapy for recurrent/metastatic disease. Must have received at least one prior line of endocrine therapy for recurrent/metastatic disease with disease progression, and the investigator judges that further benefit from endocrine therapy is not possible.
  4. Documented radiological disease progression (during or after the most recent therapy).
  5. ECOG performance status of 0 or 1.
  6. Life expectancy ≥ 12 weeks.
  7. At least one extracranial measurable lesion as a target lesion according to RECIST v1.1 criteria.
  8. Adequate function of major organs.
  9. Pregnancy and contraception: Women of childbearing potential (WOCBP) must agree to use highly effective contraception from study screening until 7 months after the last dose of study drug and agree not to breastfeed; serum pregnancy test result must be negative within 7 days before the first dose.
  10. The patient voluntarily participates in this study, signs the informed consent form, has good compliance, and is willing to cooperate with visits and study-related procedures.

  1. Presence of leptomeningeal metastasis/carcinomatous meningitis, spinal cord compression, or active central nervous system metastases.
  2. Patients with only skin or brain lesions as target lesions.
  3. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.
  4. Presence of carcinomatous lymphangitis, or third-space fluid accumulation that cannot be controlled by methods such as drainage.
  5. Prior surgery, chemotherapy, immunotherapy, or macromolecular targeted therapy within 4 weeks before the first dose; prior endocrine therapy, chemotherapy with 5-FU analogs, or radiotherapy within 2 weeks before the first dose; small molecule targeted agents require a washout period of 2 weeks or 5 half-lives; other investigational drugs require a washout period of 4 weeks or 5 half-lives before the first dose.
  6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within 2 weeks before the first dose for therapeutic intent.
  7. History of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.
  8. Clinically significant cardiovascular disease, such as severe/unstable angina, symptomatic congestive heart failure, etc.; clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; myocardial infarction or cerebrovascular accident within 6 months before the first dose.
  9. Participants with known or suspected interstitial lung disease; other moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity and severely affect respiratory function within 3 months before the first dose; and any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement.
  10. Known hereditary or acquired bleeding tendency.
  11. Active hepatitis B, hepatitis C, or cirrhosis; or severe infection requiring control with antibiotics, antivirals, or antifungals.
  12. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 (according to NCI-CTCAE v5.0).
  13. Any other severe physical or mental illness or laboratory abnormality that may increase the risk associated with study participation, interfere with study results, or any other condition for which the investigator considers the patient unsuitable for participation in this study.
Jiangsu HengRui Medicine Co., Ltd. logoHENGRUI PHARMA143 estudos clínicos ativos para explorar
Contato central do estudo
Contato: Xia Zhang, +86-0518-82342973, [email protected]
1 Locais do estudo em 1 países

Beijing Municipality

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality, 100021, China
Binghe Xu, Contato, +86-010-67781331, [email protected]
Binghe Xu, Investigador principal